In this study, a comprehensive survey of hot spot mutations in the EGFR, KRAS, BRAF, TP53 and ALK genes in 184 NSCLC patients using the single allelic molecule counting SMART assay revealed highly heterogeneous tumour mutation profiles regardless of disease stage. This evidence concerns the gene KRAS and neoplasm.